文献リスト

1）Kondo M, Yano Y, Shirataka M, et al. Porphyrias in Japan: compilation of all cases reported through 2002. Int J Hematol. 2004; 79: 448-56

2）Jalil S, Grady JJ, Lee C, et al. Associations among behavior-related susceptibility factors in porphyria cutanea tarda. Clin Gastroenterol Hepatol. 2010; 8: 297-302, 302. e1

3）Bonkovsky HL, Siao P, Roig Z, et al. Case records of the Massachusetts General Hospital. Case 20-2008. A 57-year-old woman with abdominal pain and weakness after gastric bypass surgery. N Engl J Med. 2008; 358: 2813-25

4）Harrison-Findik DD, Klein E, Crist C, et al. Iron-mediated regulation of liver hepcidin expression in rats and mice is abolished by alcohol. Hepatology. 2007; 46: 1979-85

5）Ohtake T, Saito H, Hosoki Y, et al. Hepcidin is down-regulated in alcohol loading. Alcohol Clin Exp Res. 2007; 31(1 Suppl): S2-8

6）Phillips JD, Bergonia HA, Reilly CA, et al. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci U S A. 2007; 104: 5079-84

7）Kristiansen MG, Lochen ML, Gutteberg TJ, et al. Hepatitis C virus infection was not found in patients with sporadic porphyria cutanea tarda, membranoproliferative glomerulonephritis or membranous glomerulonephritis in Northern Norway. Scand J Gastroenterol. 2009; 44: 894-6

8）Miura K, Taura K, Kodama Y, et al. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology. 2008; 48: 1420-9

9）Degenhardt T, Vaisanen S, Rakhshandehroo M, et al. Peroxisome proliferator-activated receptor alpha controls hepatic heme biosynthesis through ALAS1. J Mol Biol. 2009; 388: 225-38

10）Delaby C, To-Figueras J, Deybach JC, et al. Role of two nutritional hepatic markers (insulin-like growth factor 1 and transthyretin) in the clinical assessment and follow-up of acute intermittent porphyria patients. J Intern Med. 2009; 266: 277-85

11）Hengstman GJ, de Laat KF, Jacobs B, et al. Sensorimotor axonal polyneuropathy without hepatic failure in erythropoietic protoporphyria. J Clin Neuromuscul Dis. 2009; 11: 72-6

12）Whatley SD, Ducamp S, Gouya L, et al. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet. 2008; 83: 408-14

13）Bylesjo I, Wikberg A, Andersson C. Clinical aspects of acute intermittent porphyria in northern Sweden: a population-based study. Scand J Clin Lab Invest. 2009; 69: 612-8

14）Andersson C, Innala E, Backstrom T. Acute intermittent porphyria in women: clinical expression, use and experience of exogenous sex hormones. A population-based study in northern Sweden. J Intern Med. 2003; 254: 176-83

15）Eales L, Dowdle EB, Sweeney GD. The acute porphyric attack. I. The electrolyte disorder of the acute porphyric attack and the possible role of delta-aminolaevulic acid. S Afr Med. J. 1971: 89-97

16）Thadani H, Deacon A, Peters T. Diagnosis and management of porphyria. BMJ. 2000; 320: 1647-51

17）Pischik E, Bulyanitsa A, Kazakov V, et al. Clinical features predictive of a poor prognosis in acute porphyria. J Neurol. 2004; 251: 1538-41

18）Sardh E, Andersson DE, Henrichson A, et al. Porphyrin precursors and porphyrins in three patients with acute intermittent porphyria and end-stage renal disease under different therapy regimes. Cell Mol Biol (Noisy-le-grand). 2009; 55: 66-71

19）Gonzalez Estrada A, Garcia-Morillo S, Gomez Morales L, et al. Chronic elevation of liver enzymes in acute intermittent porphyria initially misdiagnosed as autoimmune hepatitis. Int J Hepatol. 2011; 2011: 392049

20）Andersson C, Wikberg A, Stegmayr B, et al. Renal symptomatology in patients with acute intermittent porphyria. A population-based study. J Intern Med. 2000; 248: 319-25

21）Unzu C, Sampedro A, Sardh E, et al. Renal failure affects the enzymatic activities of the three first steps in hepatic heme biosynthesis in the acute intermittent porphyria mouse. PLoS One. 2012; 7: e32978

22）Marsden JT, Chowdhury P, Wang J, et al. Acute intermittent porphyria and chronic renal failure. Clin Nephrol. 2008; 69: 339-46

23）Simon NG, Herkes GK. The neurologic manifestations of the acute porphyrias. J Clin Neurosci. 2011; 18: 1147-53

24）Andersson C, Nilsson A, Backstrom T. Atypical attack of acute intermittent porphyria--paresis but no abdominal pain. J Intern Med. 2002; 252: 265-70

25）Gonzalez-Arriaza HL, Bostwick JM. Acute porphyrias: a case report and review. Am J Psychiatry. 2003; 160: 450-9

26）Ellencweig N, Schoenfeld N, Zemishlany Z. Acute intermittent porphyria: psychosis as the only clinical manifestation. Isr J Psychiatry Relat Sci. 2006; 43: 52-6

27）Ridley A. The neuropathy of acute intermittent porphyria. Q J Med. 1969; 38: 307-33

28）Albers JW, Robertson WC, Jr, Daube JR. Electrodiagnostic findings in acute porphyric neuropathy. Muscle Nerve. 1978; 1: 292-6

29）Hsieh CH, Tsai HH, Lu TH, et al. Acute inter-mittent porphyria with peripheral neuropathy complicated by small-fiber neuropathy. Neuro-pathology. 2007; 27: 133-8

30）Cavanagh JB, Mellick RS. On the nature of the peripheral nerve lesions associated with acute intermittent porphyria. J Neurol Neurosurg Psychiatry. 1965; 28: 320-7

31）Suarez JI, Cohen ML, Larkin J, et al. Acute intermittent porphyria: clinicopathologic correlation. Report of a case and review of the literature. Neurology. 1997; 48: 1678-83

32）Santosh PJ, Malhotra S. Varied psychiatric manifestations of acute intermittent porphyria. Biol Psychiatry. 1994; 36: 744-7

33）Solinas C, Vajda FJ. Epilepsy and porphyria: new perspectives. J Clin Neurosci. 2004; 11: 356-61

34）Utz N, Kinkel B, Hedde JP, et al. MR imaging of acute intermittent porphyria mimicking reversible posterior leukoencephalopathy syndrome. Neuroradiology. 2001; 43: 1059-62

35）Celik M, Forta H, Dalkilic T, et al. MRI reveals reversible lesions resembling posterior reversible encephalopathy in porphyria. Neuroradiology. 2002; 44: 839-41

36）Bartynski WS. Posterior reversible encephalo-pathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol. 2008; 29: 1043-9

37）Bartynski WS. Posterior reversible encephalo-pathy syndrome, part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol. 2008; 29: 1036-42

38）Felitsyn N, McLeod C, Shroads AL, et al. The heme precursor delta-aminolevulinate blocks peripheral myelin formation. J Neurochem. 2008; 106: 2068-79

39）Albers JW, Fink JK. Porphyric neuropathy. Muscle Nerve. 2004; 30: 410-22

40）Kaji R. Physiology of conduction block in multifocal motor neuropathy and other demye-linating neuropathies. Muscle Nerve. 2003; 27: 285-96

41）Lin CS, Krishnan AV, Lee MJ, et al. Nerve function and dysfunction in acute intermittent porphyria. Brain. 2008; 131(Pt 9): 2510-9

42）Kauppinen R, von und zu Fraunberg M. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families. Clin Chem. 2002; 48: 1891-900

43）Lim CK, Peters TJ. Urine and faecal porphyrin profiles by reversed-phase high-performance liquid chromatography in the porphyrias. Clin Chim Acta. 1984; 139: 55-63

44）Aarsand AK, Petersen PH, Sandberg S. Estima-tion and application of biological variation of urinary delta-aminolevulinic acid and porphobilinogen in healthy individuals and in patients with acute intermittent porphyria. Clin Chem. 2006; 52: 650-6

45）Foran SE, Abel G. Guide to porphyrias. A historical and clinical perspective. Am J Clin Pathol. 2003; 119 Suppl: S86-93

46）Sardh E, Harper P, Andersson DE, et al. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks. Eur J Intern Med. 2009; 20: 201-7

47）Floderus Y, Sardh E, Moller C, et al. Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion. Clin Chem. 2006; 52: 701-7

48）Akagi R, Kato N, Inoue R, et al. delta-Aminolevulinate dehydratase (ALAD) porphyria: the first case in North America with two novel ALAD mutations. Mol Genet Metab. 2006; 87: 329-36

49）Puy H, Deybach JC, Lamoril J, et al. Molecular epidemiology and diagnosis of PBG deaminase gene defects in acute intermittent porphyria. Am J Hum Genet. 1997; 60: 1373-83

50）Rosipal R, Lamoril J, Puy H, et al. Systematic analysis of coproporphyrinogen oxidase gene defects in hereditary coproporphyria and muta-tion update. Hum Mutat. 1999; 13: 44-53

51）Whatley SD, Puy H, Morgan RR, et al. Variegate porphyria in Western Europe: identification of PPOX gene mutations in 104 families, extent of allelic heterogeneity, and absence of correlation between phenotype and type of mutation. Am J Hum Genet. 1999; 65: 984-94

52）Lamoril J, Puy H, Whatley SD, et al. Charac-terization of mutations in the CPO gene in British patients demonstrates absence of genotype-phenotype correlation and identifies relationship between hereditary coproporphyria and hardero-porphyria. Am J Hum Genet. 2001; 68: 1130-8

53）Grandchamp B, Picat C, Kauppinen R, et al. Molecular analysis of acute intermittent por-phyria in a Finnish family with normal erythro-cyte porphobilinogen deaminase. Eur J Clin Invest. 1989; 19: 415-8

54）Whatley SD, Mason NG, Woolf JR, et al. Diagnostic strategies for autosomal dominant acute porphyrias: retrospective analysis of 467 unrelated patients referred for mutational analysis of the HMBS, CPOX, or PPOX gene. Clin Chem. 2009; 55: 1406-14

55）Anderson KE, Bloomer JR, Bonkovsky HL, et al. Recommendations for the diagnosis and treat-ment of the acute porphyrias. Ann Intern Med. 2005; 142: 439-50

56）Harper P, Wahlin S. Treatment options in acute porphyria, porphyria cutanea tarda, and erythro-poietic protoporphyria. Curr Treat Options Gastro-enterol. 2007; 10: 444-55

57）Sood N, Buntin MB, Escarce JJ. Does how much and how you pay matter? Evidence from the inpatient rehabilitation care prospective payment system. J Health Econ. 2008; 27: 1046-59

58）Mustajoki P, Nordmann Y. Early administration of heme arginate for acute porphyric attacks. Arch Intern Med. 1993; 153: 2004-8

59）Siegert SW, Holt RJ. Physicochemical properties, pharmacokinetics, and pharmacodynamics of intravenous hematin: a literature review. Adv Ther. 2008; 25: 842-57

60）Mustajoki P, Tenhunen R, Pierach C, et al. Heme in the treatment of porphyrias and hematological disorders. Semin Hematol. 1989; 26: 1-9

61）Puy H, Gouya L, Deybach JC. Porphyrias. Lancet 2010; 375: 924-37

62）Tatum WO 4th, Zachariah SB. Gabapentin treat-ment of seizures in acute intermittent porphyria. Neurology. 1995; 45: 1216-7

63）Paul F, Meencke HJ. Levetiracetam in focal epilepsy and hepatic porphyria: a case report. Epilepsia. 2004; 45: 559-60

64）Zaatreh MM. Levetiracetam in porphyric status epilepticus: a case report. Clin Neuropharmacol. 2005; 28: 243-4

65）Bhatia R, Vibha D, Srivastava MV, et al. Use of propofol anesthesia and adjunctive treatment with levetiracetam and gabapentin in managing status epilepticus in a patient of acute inter-mittent porphyria. Epilepsia. 2008; 49: 934-6

66）Seth AK, Badminton MN, Mirza D, et al. Liver transplantation for porphyria: who, when, and how? Liver Transpl. 2007; 13: 1219-27

67）Dowman JK, Gunson BK, Bramhall S, et al. Liver transplantation from donors with acute inter-mittent porphyria. Ann Intern Med. 2011; 154: 571-2

68）Kauffman L, Evans DI, Stevens RF, et al. Bone-marrow transplantation for congenital erythro-poietic porphyria. Lancet. 1991; 337: 1510-1

69）Taibjee SM, Stevenson OE, Abdullah A, et al. Allogeneic bone marrow transplantation in a 7-year-old girl with congenital erythropoietic porphyria: a treatment dilemma. Br J Dermatol. 2007; 156: 567-71

70）Singh S, Khanna N, Kumar L. Bone marrow transplantation improves symptoms of congenital erythropoietic porphyria even when done post puberty. Indian J Dermatol Venereol Leprol. 2012; 78: 108-11

71）Johansson A, Nowak G, Moller C, et al. Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria. Mol Genet Metab. 2004; 82: 20-6

72）Paneda A, Vanrell L, Mauleon I, et al. Effect of adeno-associated virus serotype and genomic structure on liver transduction and biodistribu-tion in mice of both genders. Hum Gene Ther. 2009; 20: 908-17

73）Unzu C, Sampedro A, Mauleon I, et al. Sustained enzymatic correction by rAAV-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice. Mol Ther. 2011; 19: 243-50

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp